BAXDELA (delafloxacin) | A pathway for ABSSSI treatment

Baxdela is your Path Forward.

Multiple factors impact the treatment of acute bacterial skin and skin structure infections (ABSSSI). BAXDELA is your path forward.

aBAXDELA clinical trials included a distribution of patients with obesity, hypertension, diabetes, and renal impairment (eGFR > 15 mL/min/1.73 m2).

Pathway to Efficacy

Diabetes, age, obesity—multiple factors impact ABSSSI treatment.

See Baxdela Results

Explore Safety
& Tolerability

See Baxdela Outcomes

Simplify Dosing & Administration

Straightforward dosing in IV, oral, or IV to oral.

See Baxdela Options

Pathway to
Pathogen Coverage

Microbiological activity against susceptible gram-negative and gram-positive pathogens, including MRSA.

See Response Rates

Simplify
Patient Access

For hospital or home, streamline access with MelintAssist.

Explore Baxdela Options

Next: Introduction

BAXDELA is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.